AQP4 antibody selection: when a membrane or very large target defeats the default protocol

What each target demands

1. Do not boil a multipass membrane protein. Heating a multipass membrane channel in sample buffer aggregates it, and the aggregate sits in the well rather than running. Incubating at a lower temperature, commonly thirty seven or seventy degrees, is what makes the band appear, and this single change rescues a great many apparently dead antibodies.
2. Use a low percentage gel for very large targets. A protein of several hundred kilodaltons will not resolve on a standard gel and may barely leave the stacking layer. A low percentage or gradient gel, a longer run and a wet transfer with extended time are what get it onto a membrane.
3. Check whether the epitope is conformational. Antibodies raised against folded extracellular loops often fail on a denatured blot and work well on intact cells. Read which immunogen was used and which applications carry actual data, because the application list is frequently aspirational.
4. Expect modification to change the picture. Ubiquitination and other modifications produce ladders and shifted bands that look like non-specific binding. For targets in that biology, a smear or a ladder may be the real signal and a single clean band may be the artefact.
5. Use a genetic negative wherever one exists. A knockout or knockdown sample is the control that settles specificity for all three. Where none exists, an overexpression positive and a second antibody against a different epitope together are the next best evidence.

Extraction before electrophoresis

Membrane proteins need a detergent that solubilises without denaturing the epitope, and the choice interacts with the antibody. A lysate that looks fine by total protein can be missing the target entirely if the detergent did not extract it.

For very large targets, shearing during lysis fragments them. Gentle lysis and avoiding repeated pipetting matter more here than in ordinary work.

Immunostaining these targets

Retrieval conditions differ substantially between a membrane channel and a cytoplasmic ligase, so test citrate and a higher pH buffer side by side on a known positive rather than inheriting a protocol.

For a channel with a strongly polarised distribution, the staining pattern itself is part of the validation: a reagent that stains the right cells in the wrong subcellular pattern is suspect regardless of intensity.

Buying and recording

Read which application each piece of datasheet evidence supports, and buy against the application you will run. For all three of these targets, a reagent good in one application and poor in another is common and expected.

Record the catalogue number, lot, dilution and the exact denaturation and transfer conditions in the method. For targets this protocol-sensitive, a method without those numbers cannot be repeated by anyone including you.

A th antibody and the catecholamine neurons it marks

Tyrosine hydroxylase is the rate limiting enzyme of catecholamine synthesis, so a th antibody marks dopaminergic and noradrenergic neurons and is the standard count in Parkinson models. The count rather than the intensity is the readout, with a stated sampling rule through the region. Its level falls before cells die, so a fall in staining is not by itself cell loss and a second marker is what separates them.

A tspo antibody and the glial activation marker

TSPO is an outer mitochondrial membrane protein used as a marker of activated glia and as an imaging target, so a tspo antibody is read beside a microglial or astrocytic marker rather than alone. A common polymorphism changes ligand binding in the imaging use, which is a caveat carried into any comparison with a scan. It is small and membrane bound, so the fraction matters.

An ncam1 antibody and the polysialylated form

NCAM1 carries a long polysialic acid chain in developing and plastic tissue, and that form is what marks immature neurons, so an ncam1 antibody has to say whether it detects the protein backbone or the sugar. The two give different patterns in the same section. Apparent mass is far above the calculated value because of the sugar, and an enzymatic removal lane is the control that proves it.

A gephyrin antibody and the inhibitory postsynapse

Gephyrin clusters inhibitory receptors, so a gephyrin antibody marks the postsynaptic side opposite a GABAergic terminal and the useful image is that apposition rather than either alone. It is read as puncta with a counting rule. The protein oligomerises and the clusters are detergent resistant, so an insoluble fraction holds the assembled pool a standard lysate loses.

An mglur5 antibody and a receptor read for a target

mGluR5 is a multipass G protein coupled receptor and a therapeutic target, so an mglur5 antibody carries the usual family risk: a clone raised on a conserved region reports its relatives. Knockout validation is the evidence worth paying for. It dimerises, so a non reducing gel can show a higher band, and the expected masses belong in the method rather than being inferred.

A glua1 antibody and the subunit that traffics

GluA1 containing receptors move in and out of the synapse during plasticity, so a glua1 antibody is used for surface versus internal pools rather than for total level, and a surface biotinylation or a live labelling step is what makes that distinction. The subunit is phosphorylated at named residues that control trafficking, so a phospho clone with its residue stated is the companion reagent.

An stmn2 antibody and a marker of axonal integrity

STMN2 falls when the RNA binding protein that regulates its splicing is lost, which is why it has become a readout in motor neuron disease rather than a general neuronal marker. An stmn2 antibody is therefore interpreted against that pathway, and a truncated transcript means the epitope position decides what is seen. It is low abundance, so a positive control line is part of the blot.

A cb1 antibody and the tissue it is used on

A cb1 antibody reports the cannabinoid receptor on presynaptic terminals, and the staining pattern is punctate rather than cell filling, which is what a validated clone shows and a poor one does not. A knockout control is available for this target and remains the only way to show that a band or a punctum is real.

Common questions

Why does my membrane protein not appear on a western blot?

Most often because the sample was boiled and the protein aggregated in the well. Try thirty seven or seventy degrees instead of ninety five, and check whether the antibody's epitope is conformational and therefore lost on a denatured blot.

How do I blot a very large protein?

A low percentage or gradient gel, a long run, and a wet transfer with extended time and often reduced methanol. Standard conditions leave proteins of several hundred kilodaltons in the gel, which reads as an absent target.

What does a conformational epitope mean in practice?

The antibody recognises the folded shape, so it works on intact cells and fails on a denatured blot. Applications are not interchangeable for such a reagent and the datasheet should show data per application.

Why is my blot a ladder rather than a band?

For targets in ubiquitin biology, a ladder is often the real signal rather than non-specific binding. Interpreting it needs the genetic control and a treatment that changes the modification, not a cleaner antibody.

Browse by service class

• Compare Gene synthesis on advertised prices